Evidence map›Paper›PMID 9065291›Full record

ReviewAnnals of surgery1997

Clinical uses of gut peptides.

J Geoghegan, T N Pappas

Abstract readReview
In one paragraph

Review in Annals of surgery, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

J GeogheganDepartment of General and Visceral Surgery, Friedrich-Schiller University Jena, Germany.
T N Pappas

Funding

REGULATION OF FOOD INTAKE--BRAIN AND GUT MEDIATORSR29DK040790 · NIDDK · DUKE UNIVERSITY · PI PAPPAS, THEODORE · 1989 to 1993
–
NIDDK NIH HHS R29 DK 40790-01
6 · The paper itself

Abstract

objectiveThe authors review clinical applications of gut-derived peptides as diagnostic and therapeutic agents. SUMMARY BACKGROUND DATA: An increasing number of gut peptides have been evaluated for clinical use. Earlier uses as diagnostic agents have been complemented more recently by increasing application of gut peptides as therapeutic agents.

methodThe authors conducted a literature review.

resultsCurrent experience with clinical use of gut peptides is described. Initial clinical applications focused on using secretomotor effects of gut peptides in diagnostic tests, many of which have now fallen into disuse. More recently, attention has been directed toward harnessing these secretomotor effects for therapeutic use in a variety of disorders, and also using the trophic effects of gut peptides to modulate gut mucosal growth in benign and malignant disease. Gut peptides have been evaluated in a variety of other clinical situations including use as adjuncts to imaging techniques, and modification of behaviors such as feeding and panic disorder.

conclusionsGut peptides have been used successfully in an increasing variety of clinical conditions. Further refinements in analogue and antagonist design are likely to lead to even more selective agents that may have important clinical applications. Further studies are needed to identity and evaluate these new agents.

Indexed as

Adenoma, Islet CellCholecystokininGastrinsGastrointestinal HormonesGlucagonHumansInsulinMotilinPancreatic PolypeptideSecretinSomatostatinCholecystokininGastrinsGastrointestinal HormonesGlucagonInsulinMotilinPancreatic PolypeptideSecretinSomatostatin

Identifiers

PMID9065291
PMCPMC1190643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.